Advances in cellular and molecular immunology have led to the characterization of leukemia-specific T-cell antigens and to the development of strategies for effective augmentation of T-cell immunity in leukemia patients. While several leukemia-related antigens have been identified, this review focuses on the Wilms' tumor 1 (WT1) antigen and the proteinase 3 (Pr3) antigen that are overexpressed in leukemic cells and are already being used in the clinical setting. Moreover, WT1 is also overexpressed in a vast number of nonhematological solid tumors, thereby expanding its use as a promising target for cancer vaccines. Examples of spontaneous immune responses against WT1 and Pr3 in leukemia patients are presented and the potential of WT1 and Pr3 for adoptive T-cell immunotherapy of leukemia is discussed. We also elaborate on the use of professional antigen-presenting cells loaded with mRNA encoding WT1 exploiting the advantage of broad HLA coverage for therapeutic vaccination purposes. Finally, the summarized data underscore the potential of WT1 for the manipulation of T-cell immunity in leukemia and in cancer in general, that will likely pave the way for the development of more effective and generic cancer vaccines.
Introduction
Despite major advances in the biology and therapy of leukemia, most patients will die from their disease. Therefore, new avenues in the treatment of leukemia such as immunotherapy, also called biological therapy, are being actively pursued. Remissions have been achieved in leukemia patients after allogeneic stem cell transplantation (whether or not combined with donor lymphocyte infusions (DLI)), demonstrating the presence of reactive T cells that can eradicate leukemic cells (called graft-versus-leukemia effect). [1] [2] [3] [4] [5] While acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) can be susceptible to DLI (albeit less than chronic myeloid leukemia (CML)), this treatment fails to achieve and maintain remissions in many patients and can induce undesirable side effects such as acute and chronic graft-versus-host disease (GVHD) and pancytopenia. These observations emphasize the need to develop leukemia-targeted autologous immunotherapy approaches, capitalizing on the use of defined leukemiaassociated antigens that are preferentially expressed by most leukemia types. In this context, the goal would be either to expand ex vivo CD8 þ cytotoxic T lymphocytes (CTL) specific for leukemia-associated antigens (adoptive T-cell immunotherapy) or to actively induce leukemia antigen-specific T-cell immunity in vivo (active specific immunotherapy).
Leukemia-associated antigens

Unique leukemia antigens
This group of antigens arise from aberrant fusion proteins produced as a result of a genetic translocation in leukemic cells. These fusion proteins harbor antigenic epitopes at the fusion region that may be recognized as foreign by T cells. For CML, the best studied example is the bcr-abl fusion protein derived from the t(9;22) translocation against which cytotoxic T-cell responses have been detected in CML patients. 6, 7 In acute leukemia, the ETV6-AML1 (or TEL-AML1) fusion protein derived from t(12;21) translocation can be found in a proportion of ALL. CD8 þ T-cell responses against an HLA n A0201-restricted epitope (RIAECILGM) from the ETV6-AML1 fusion protein can be generated both in healthy donors and in ALL patients. 8 Other examples of acute leukemia fusion proteins to which in vitro T-cell responses have been generated in healthy donors include PML-RARa 9 derived from the t(15;17) translocation and dekcan 10 derived from the t(6;9) translocation. Hence, it is possible to target leukemia cells by exploiting these unique leukemiaspecific antigens but these translocations are not universal for all leukemias, which limits their applicability as a general approach for leukemia immunotherapy.
Overexpressed leukemia-associated antigens
This group of antigens comprises nonpolymorphic proteins that are expressed by leukemic cells at much higher levels than by normal cells, and have therefore emerged as promising targets for adoptive T-cell therapy or as part of antigen-specific vaccine formulations. In many cases, these proteins also seem to contribute to the malignant phenotype, which is favorable for design of tumor vaccines because of the decreased risk of generation of tumor antigen-loss variants. The expression of these proteins on some normal tissues could restrict the repertoire of reactive T cells that are present in vivo because of self-tolerance mechanisms. However, by optimizing T-cell culture conditions, it has been possible to isolate rare T cells from normal donors with sufficient avidity for self-antigens to recognize leukemic cells. Examples include proteinase 3 (Pr3), Wilms' tumor 1 protein (WT1), human telomerase reverse transcriptase (hTERT), survivin, cytochrome P450 1B1 (CYPB1), immature laminin receptor protein (OFA-iLRP) and human neutrophil elastase (HNE). Most likely, microarray analysis of expression profiles in leukemic cells will identify additional candidates in this category. hTERT is a component of the ribonucleoprotein enzyme telomerase, 11, 12 which is overexpressed in 85% of cancer cells but not in normal cells, implying the possibility of using hTERT as a universal candidate tumor antigen for the design of cancer vaccines (reviewed by Kelland 13 ). 14, 15 Survivin is a new member of the apoptosis inhibitor gene family and was reported to be expressed at high levels in cancerous but not normal tissues. 16 Andersen et al 17 detected spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia and melanoma patients both in situ as well as ex vivo. Moreover, survivin-reactive T cells were shown to be cytotoxic against HLA-matched tumors of different tissue types. Also, dendritic cells (DC) pulsed with survivin mRNA have been shown to induce leukemia-specific CTL that were able to lyse both survivin-positive leukemia cell lines and primary leukemic cells in vitro. 18, 19 CYP1B1 is an extrahepatic cytochrome P450 enzyme that has been associated with the activation of environmental carcinogens. Expression of CYP1B1 is upregulated early during malignant transformation and overexpressed in most human malignancies with minimal expression on critical healthy tissues. Importantly, CYP1B1-derived HLA-A n 0201-restricted peptides have been identified and the induction of CYP1B1-specific T cells was demonstrated in both healthy donors and cancer patients. 20, 21 OFA-iLRP is an evolutionary conserved protein that has been detected in humans and appears to dimerize after acylation to form the high-affinity mature laminin receptor protein. OFA-iLRP might serve as a cofactor to stabilize the binding of laminin to cell surface integrins. Siegel et al 22 demonstrated that OFA-iLRP is abundantly expressed on various leukemic cell lines but also on malignant blasts of patients with AML. Furthermore, using OFA-iLRP RNA-loaded DC, they showed that OFA-iLRP can be used as a target for T-cell-based immunotherapeutic strategies against hematologic malignancies. 22 HNE and Pr3 are myeloid tissue-restricted serine proteases, aberrantly expressed by myeloid leukemia cells. Pr3 and HNE share the PR1 peptide sequence that induces HLA-A n 0201-restricted cytotoxic T cells (CTLs) with antileukemia reactivity. 23 At present, WT1 [24] [25] [26] [27] and Pr3 28 represent antigens that are already being used in clinical trials for leukemia patients and their use for development of leukemia vaccines is further discussed in detail.
Biology of WT1 and Pr3
WT1 was originally described as a tumor suppressor gene in pediatric renal tumors and identified as a zinc-finger transcription factor located on chromosome 11. 29, 30 The WT1 gene is essential during embryogenesis, especially during the development of the kidney and the genitourinary system. [31] [32] [33] WT1 is expressed during life in a time-and tissue-specific manner and has a function in the regulation of growth and differentiation. 31 After birth, low-level expression is restricted to a few cell types including hematopoietic stem cells, myoepithelial progenitor cells, renal podocytes, Sertoli cells of the testis and granulosa cells of the ovary. More than 10 years ago, overexpression of the WT1 gene was demonstrated in most types of leukemia, regardless of the leukemia subtype, including AML, ALL and CML. [34] [35] [36] Interestingly, from experiments with WT1 antisense oligomers, WT1 overexpression was shown to be required for the uncontrolled proliferation and defective differentiation of acute leukemia cells, suggesting involvement of WT1 in leukemogenesis. 35, 37, 38 Furthermore, WT1 can serve as a marker for disease burden and diagnosis of minimal residual disease. The limited expression of WT1 in normal tissues in adults suggests that WT1 can be an immunological target for leukemia therapy. [39] [40] [41] [42] [43] Importantly, overexpression of WT1 has also been reported in a number of solid cancers such as the lung, ovarian, thyroid, testicular, gastric, colon and breast cancer, 37, [44] [45] [46] [47] which underscores the potential use of WT1 as a universal tumor-associated antigen candidate for immunotherapy of cancer.
Pr3 is a serine protease that is induced at the promyelocyte stage of differentiation and stored in azurophilic granules of promyelocytes.
48 Pr3 belongs to the group of primary granule proteins (PGP), including HNE and cathepsin-G, that are aberrantly expressed in myeloid leukemias. It is known to be a target of autoantibodies in patients who have Wegener's granulomatosis. Importantly, it may be involved in the process of leukemogenesis because antisense oligodeoxynucleotides against Pr3 are able to inhibit cell proliferation and to induce differentiation in an HL60 promyelocytic leukemia cell line.
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Pr3 is highly overexpressed by cells from CML patients and differentially expressed by some AML cells, but is absent on cells from ALL patients. 50 Therefore, Pr3, and PGP in general, are of great interest as a source of myeloid leukemia-restricted antigens for immunotherapy. 51 
Spontaneous T-cell reactivity to WT1 and Pr3 in leukemia patients
The fact that increased antibody levels against WT1 can be found in leukemia patients as compared to healthy volunteers 52, 53 provided direct in vivo evidence that WT1 is immunogenic in humans. Interestingly, Wu et al 54 showed that predominantly T helper cell type 1 (Th1)-type WT1 antibodies (IgG 1 , IgG 2 and IgG 3 ) were significantly increased as compared to Th2-type WT1 IgG 4 antibodies, favoring Th1-biased cellular immune responses against WT1 protein, which is considered to be pivotal for generation of CD8 þ cytotoxic anti-tumor T-cell responses. However, due to the physiological expression of WT1 in some tissues, concerns exist that anti-WT1 T-cell responses, especially those mediated by high-avidity T cells, are prone to be rendered tolerant. 55 Nevertheless, Rezvani et al 56 showed that interferon (IFN)-g-producing CD8 þ T cells directed against WT1 and PR1 (ie the dominant HLA-A n -0201 epitope from Pr3) could be detected in CML patients before and after allogeneic hematopoietic stem cell transplantation (HSCT) and in healthy donors. Responses were higher in patients with CML compared with healthy donors and highest after allogeneic HSCT. Furthermore, low-avidity CD8 þ T-cell responses to WT1 and PR1 were more abundant in CML patients than highavidity responses, in contrast to CD8 þ T-cell responses in healthy donors. 56 This is concordant with the data from Molldrem et al 57 reporting that the T-cell repertoire in CML patients might be depleted of high-avidity PR1-specific T cells by the tumor itself. In contrast to WT1, there is evidence that the number of T cells that are specific for PR1 is increased in CML patients who have been treated with IFN-a or allogeneic HSCT, and their presence correlates with complete remission. 58 Furthermore, T cells that are specific for PR1 are more frequently identified in CML patients who are treated with IFN-a, compared with those on imatinib, which could be related to the upregulation of Pr3 expression that is induced by IFN-a. 59 Cellular immunotherapy of leukemia A Van Driessche et al
Scheibenbogen et al 60 reported spontaneous T-cell reactivity against WT1 and Pr3 in eight of 15 HLA-A2-positive AML patients by IFN-g ELISPOT assay and/or intracellular IFN-g staining, providing evidence for spontaneous T-cell reactivity against defined antigens, also in AML patients.
Recently, the group of Sugiyama 61 and we (unpublished results) showed by WT1-specific HLA-A2 tetramer analysis that WT1-specific CD8 þ T-cell frequencies were significantly higher in patients with leukemia or solid tumors (breast and lung carcinoma) than in healthy volunteers. These results indicate that patients with WT1-expressing tumor cells responded to the WT1 protein derived from the tumor cells and spontaneously elicited WT1-specific CD8 þ T cells.
Potential of WT1 and Pr3 for adoptive immunotherapy
WT1-specific T cells
Several groups reported on the ex vivo induction and expansion of autologous WT1 peptide-specific CTL in healthy donors after multiple restimulations with antigen-presenting cells (APC) that had been pulsed with synthetic WT1 peptides, selected by prediction algorithms for binding to HLA-A n 0201 or HLA-A n 2402. 24, 26, 27, 56, 60, 62 Recently, an HLA-A n 01-restricted WT1 epitope was characterized by MHC binding prediction algorithm and confirmed to have a high immunogenicity because reactive CTL could be easily detected in AML patients and allogeneic HSCT recipients. 63 As a means to avoid possible selftolerance to WT1, the group of Stauss combined the high-avidity nature of an allogeneic T-cell response with an antigen-specific approach through the in vitro generation of leukemia-specific allorestricted human CTL. 55, 64 Using this method, high-avidity CTL could be established from HLA-A2-negative donors recognizing HLA-A2-presented epitopes from overexpressed leukemia-associated proteins, such as WT1, CD45 and CD68. 24, 55, [65] [66] [67] [68] [69] At present, established human WT1-specific CTL clones, such as TAK-1, 70 NIM-1 62 and 77, 24 have been found to induce lysis of endogenously WT1-expressing tumor cells in vitro, to inhibit in vitro colony formation by leukemic CD34 þ cells and to impair engraftment of human leukemic cells in immunodeficient NOD-SCID mice. Importantly, WT1-specific CTL did not cause damage to physiologically WT1-expressing normal cells or impair normal hematopoiesis, 71 notwithstanding the fact that WT1 expression levels in a proportion of normal CD34 þ hematopoietic progenitor and stem cells were comparable to those observed in leukemic cells. 72 In view of the important role of tumor antigen-specific CD4 þ T lymphocytes in the induction of an antitumor immune response, 73 it will be equally important to characterize WT1-derived CD4 þ T-cell antigens. So far, a high-affinity HLA-DRB1 n 0401-binding WT1 124À138 peptide and an HLA-DP n 5-binding WT1 337À347 peptide have recently been described. 74, 75 Established WT1-specific CD4 þ T cell lines proliferated and produced Th1 cytokines upon stimulation with the WT1-derived peptide and/or exhibited cytotoxicity specifically towards HLAcompatible WT1-expressing tumor cells.
PR1-specific T cells
Similar to WT1, PR1-specific T cells have been isolated from healthy donors after multiple restimulations with APC that had been pulsed with a synthetic PR1 peptide. Both high-and lowavidity T cells could be isolated from normal individuals, depending on the peptide concentration that is used for stimulation, 76 and only T cells with high avidity showed antileukemic activity. 57 T cells specific for PR1 also inhibit in vitro colony formation by leukemic but not normal CD34 þ cells. 28 HNE, also a myeloid tissue-restricted serine protease that is overexpressed by myeloid leukemia cells, shares the PR1 peptide sequence that induces HLA-A n 0201-restricted CTLs with antileukemia reactivity. Monocytes loaded with the fulllength HNE protein were able to generate potent CD4 þ and CD8 þ T-cell responses in about 50% of healthy individuals. Furthermore, it was shown that HLA-A n 0201-negative HNEspecific CTL could inhibit in vitro colony formation by leukemic CD34 þ cells, indicating that peptides other than PR1 can induce leukemia-reactive CTLs. 23 While more studies are warranted to confirm the immunogenic potential of HNE, these results suggest that HNE could be used in an HLA-A2-independent manner to induce leukemia-reactive CTLs for adoptive immunotherapy.
These results suggest that both WT1-and Pr3-derived epitopes can be targeted by antigen-specific T cells and may yield epitopes immunogenic to CD4 þ as well as CD8 þ T cells, allowing for the isolation and expansion of autologous T cells for adoptive T-cell strategies. Techniques are now well established for the isolation of human T-cell clones and individual clones can be expanded to several billion cells using appropriate culture methods. Still, at present, adoptive therapy is hampered by variables such as T-cell persistence and tumor migration. 77 Therefore, novel strategies to generate tumor-specific T cells are being explored. One promising approach is to engineer polyclonally activated T cells with transgenes encoding the T-cell receptor (TCR) a-and b-chains from previously established autologous or allorestricted leukemia-reactive T-cell clones. [78] [79] [80] [81] [82] As TCR gene transfer generally relies on integrating retroviral vectors, safety of these adoptively transferred T cells in terms of insertional mutagenesis must be warranted, for example, by introducing a conditional suicide gene such as the herpes simplex virus (HSV) thymidine kinase gene, in order to be able to destroy the transferred T cells, should adverse events occur.
Active specific immunotherapy of leukemia
Notwithstanding the wealth of in vitro and preclinical evidence regarding adoptive immunization using T cells specific for WT1 or PR1, the cumbersome nature of large-scale expansion for clinical use and unresolved matters such as CTL persistence and migration have hampered clinical trials exploring antigenspecific T-cell transfer in leukemia patients. At present, clinical trials have mainly focused on active immunization using synthetic WT1 or PR1 peptides in combination with a Montanide ISA51 adjuvant 83 or granulocyte-macrophage colonystimulating factor (GM-CSF). 84 Recently, the group of Sugiyama reported that the efficient induction of WT1-specific cytotoxic T lymphocytes correlated with cancer regression in patients with breast or lung cancer, myelodysplastic syndrome (MDS) or AML without damage to normal tissues. 61 Although the findings of the early clinical trials are promising (for a general review on peptide-based trials in leukemia, see Heslop et al; 85 for clinical WT1 peptide trials, see Keilholz et al 63 ), researchers have been exploring cellular strategies for therapeutic vaccination of leukemia in order to circumvent the limitations inherent to peptide vaccines, including prior knowledge of the peptide epitopes, need to screen for appropriate HLA haplotypes in patients, short half-life of HLA/peptide complexes and tumor epitope loss variants. Furthermore, the synthetic peptide approach might overlook (immunodominant) epitopes not predicted by classical proteasome-based computer algoritms. 86, 87 DC-based vaccination of leukemia Despite successful preclinical mouse studies in the 1990s focusing on whole-cell vaccines using irradiated leukemia cells genetically modified to express relevant cytokines and/or costimulatory molecules, [88] [89] [90] the translation to the human Cellular immunotherapy of leukemia A Van Driessche et al setting proved relatively ineffective, primarily due to the inefficiency of in vitro culture of and gene transfer into primary leukemic blasts. 91 Later, it became clear that not the tumor cells but DC, that is, professional bone marrow-derived APC, were responsible for the initiation, if any, of a tumor-specific immune response. 92 Given their privileged role as decision makers for innate and adaptive immune responses combined with the ability to culture large numbers of them in vitro starting from monocytes (extensively reviewed in Van Tendeloo et al, 91 Huang et al 92 and Banchereau and Steinman
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) and to load them ex vivo with antigens, DC have become the subject of intensive research for use in tumor vaccination protocols. [93] [94] [95] [96] While most of these trials have been performed with DC pulsed with synthetic MHC class I-restricted tumor peptides, an ideal DC-based therapy should include prolonged presentation of multiple MHC class I-and II-restricted epitopes (preferably of multiple tumor-related antigens) independent of the HLA constitution of the patient. 97 One promising method fulfilling these requirements would be to load DC with one or more mRNAs encoding the relevant antigens. Furthermore, in comparison with viral transduction, RNA-transfected DC are safe for clinical use, as mRNA has a relatively short half-life, transgene expression is transient and mRNA lacks the potential to integrate into the host genome. 98, 99 We and others already demonstrated the potency of mRNA-electroporated DC to activate antigen-specific T cells in vivo and in vitro in different antigen models, with superior or at least comparable efficiency as compared to peptide-pulsed APC. [100] [101] [102] [103] [104] [105] [106] [107] In our view, vaccination with DC transfected with WT1 RNA could be a workable immunotherapy for leukemia (or other WT1-expressing tumors). Following WT1 mRNA electroporation of DC, WT1 mRNA levels were detectable for up to 5 days postelectroporation, while none was detected in non-or mockelectroporated DC (Figure 1a ). WT1 mRNA introduced by electroporation is efficiently translated into protein and subsequently degraded by the proteasomal pathway into peptides and efficiently presented by MHC class I molecules, as shown by the stimulation of a WT1-specific T-cell clone that produces IFN-g following recognition of the HLA-A n 0201-restricted WT1 126À134 epitope. Similar results were obtained using WT1-mRNA electroporated CD40L-activated B cells (Figure 1b and c) . The latter cells, in contrast to in vitro cultured monocyte-derived DC, exhibit a high proliferative capacity and can be cultured to high numbers (10 8 cells) from a limited amount of peripheral blood in 3 weeks, which could be advantageous when multiple vaccination cycles are planned. 108, 109 These results, together with the fact that circulating WT1-specific T cells can be found in leukemia patients, provide a working platform for the design of a WT1-targeted DC vaccine for the boosting of T-cell immunity against leukemia. Moreover, this strategy can be extended to other overexpressed leukemia antigens such as Pr3, HNE, survivin 18, 19 and OFA-iLRP 22 (or even a combination of these antigens) as well as to other malignancies characterized by WT1 overexpression (Figure 2) . So far, clinical trials using RNA-transfected DC were shown to be safe and well-tolerated, and resulted in strong immune responses in most tumor patients, sometimes associated with clinical benefit ranging from complete remission to stable disease, similar to or better than immune responses obtained with other approaches. 98 However, to date, DC-based therapy is far from being standardized because of the many variables such as different DC culture protocols (leading to different types of DC), DC maturation status, dose and timing interval, route of administration, and antigen loading method for induction of both CD4 þ and CD8 þ T-cell responses. 110 In addition, and specifically for RNA-electroporated DC, the effect of different doses of electroporated RNA, the kinetics of antigen presentation following RNA electroporation and the optimal timepoint of electroporation with regard to the DC maturation status 111, 112 are important criteria that must be evaluated in carefully designed clinical trials. We are currently recruiting AML patients in remission for a phase I/II trial using WT1 mRNA-electroporated DC to investigate the feasibility, possible toxicity and/or autoimmunity and vaccination-induced WT1-specific T-cell responses. Moreover, future vaccine design should focus on two-arm trials comparing delivery of antigens or peptides (mixed with classical adjuvants) with infusion of antigen-loaded DC, in order to fully establish the adjuvant role of DC. These trials are currently underway.
Conclusions and future perspectives
Recent advances in the field of tumor immunology and T-cell activation hold promise for the induction of T-cell immunity in leukemia through active or passive immunization against overexpressed antigens such as WT1 and Pr3. New strategies including T-cell receptor engineering or priming by stimulatory DC for the ex vivo expansion of WT1 or Pr3 peptide-specific T cells have emerged as potentially powerful tools for adoptive therapy of leukemia. Importantly, therapeutic vaccination strategies using APC loaded with mRNA encoding full-length WT1 and/or other overexpressed leukemia-restricted antigens (Pr3, HNE, survivin, OFA-iLRP) are currently being pursued for the induction of antileukemia cellular immunity. More clinical trials will be necessary to evaluate both the therapeutic antitumor immunity and the risks for autoimmune effects of WT1-and Pr3-targeted therapies. Early promising results of WT1-targeted therapy in both hematological and nonhematological malignancies point to the potential of WT1 as a universal tumor antigen candidate for cancer vaccination.
